Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Methods Systematic reviews were conducted...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Breast cancer research and treatment Ročník 180; číslo 3; s. 597 - 609
Hlavní autori: Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: New York Springer US 01.04.2020
Springer
Springer Nature B.V
Predmet:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Bridged-Ring Compounds - administration & dosage
Cancer research
Care and treatment
Clinical trials
ErbB-2 protein
Female
Humans
Immunotherapy
Inhibitor drugs
Medicine
Medicine & Public Health
Meta-analysis
Metastases
Metastasis
Molecular Targeted Therapy
Monoclonal antibodies
Oncology
Pertuzumab
Receptor, ErbB-2 - antagonists & inhibitors
Review
Survival
Targeted cancer therapy
Taxoids - administration & dosage
Thrombocytopenia
Trastuzumab
Trastuzumab - administration & dosage
Treatment Outcome
Trastuzumab emtansine
Lapatinib
Pertuzumab
Capecitabine
Neratinib
Locally advanced
ISSN:0167-6806, 1573-7217, 1573-7217
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Methods Systematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints. Results The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators. Conclusions The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
AbstractList PurposeIn the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC).MethodsSystematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints.ResultsThe NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators.ConclusionsThe efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Systematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints. The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators. The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Methods Systematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse ([less than or equal to] 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints. Results The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators. Conclusions The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Methods Systematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints. Results The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators. Conclusions The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators. The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC).PURPOSEIn the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC).Systematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints.METHODSSystematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints.The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators.RESULTSThe NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators.The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.CONCLUSIONSThe efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
Audience Academic
Author Pivot, Xavier
Krop, Ian
Paracha, Noman
Diéras, Véronique
Reyes, Adriana
Urruticoechea, Ander
Author_xml – sequence: 1
  givenname: Noman
  orcidid: 0000-0002-3438-4853
  surname: Paracha
  fullname: Paracha, Noman
  email: noman.paracha@roche.com
  organization: F. Hoffmann-La Roche AG
– sequence: 2
  givenname: Adriana
  surname: Reyes
  fullname: Reyes, Adriana
  organization: F. Hoffmann-La Roche AG
– sequence: 3
  givenname: Véronique
  surname: Diéras
  fullname: Diéras, Véronique
  organization: Centre Eugène Marquis
– sequence: 4
  givenname: Ian
  surname: Krop
  fullname: Krop, Ian
  organization: Dana-Farber Cancer Institute, Harvard Medical School
– sequence: 5
  givenname: Xavier
  surname: Pivot
  fullname: Pivot, Xavier
  organization: Paul Strauss Centre, Regional Institute of Cancer
– sequence: 6
  givenname: Ander
  surname: Urruticoechea
  fullname: Urruticoechea, Ander
  organization: Onkologikoa Foundation
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32100144$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEYhQep2A_9A15IQBAvOm2SmdlkeiGUUq1QEESvQybzZjc1k6xJZuv63wUzu7VfSJmLgZnnnPfNydkvdpx3UBSvCT4iGLPjSHBTtyWmuMRNw1jJnhV7pGFVyShhO8UeJjNWzjie7Rb7MV5hjFuG2xfFbkWzAanrveLP-UraUSbj5igtAClrnFHSItAaVDIrcBAjkq5HUWpIa-Q1Wslg_BjRxflXWiYZ5pCgRwHmZgCXYZ0goGVmAkryl3RwnIKMafw9DrJDxqFlHgguRXRt0iKTsJr87BqlADJ7HaLRBYh5AdlZOETZaICULbJObccufTTTeqjLkpiQkk5BOEESxXVMMGzIyRiuN9s7SNc-_Nj4lNJJu44mviyea2kjvLp5HxTfP55_O7soL798-nx2elmqhtFUqgoop53scAsUV7olXddpSkmjWsqrnlDCVdu0dVvzrtcYGHBS942e7qEhujooPmx9l2M3QK_y2YO0Ikc0yLAWXhrx8I8zCzH3K8EIrvJFZYP3NwbB_xwhJjGYqMDaHG5OTtBq1uQ75fWEvn2EXvkx5ANPFK8445i2d9RcWhDGaZ_nqslUnM4I5y3FnGTq6D9UfnoYjMpt1CZ_fyB4d0-wAGnTIno7JuNdfAi-uZ_IbRT_mpkBugVU8DEG0LcIwWKqv9jWX-T6i039Bcsi_kikzNQZP6Vq7NPSaiuNeY6bQ7iL7QnVXz5gHpI
CitedBy_id crossref_primary_10_1016_j_pec_2025_109289
crossref_primary_10_2217_fon_2021_0742
crossref_primary_10_1016_j_critrevonc_2022_103758
crossref_primary_10_1016_j_crmeth_2023_100440
crossref_primary_10_1007_s12282_020_01192_y
crossref_primary_10_3389_fonc_2021_608781
crossref_primary_10_1177_1078155220951862
crossref_primary_10_2217_fon_2022_0894
crossref_primary_10_1007_s40261_021_01035_4
crossref_primary_10_1097_COC_0000000000000769
crossref_primary_10_1155_2022_5741437
crossref_primary_10_3389_fonc_2022_943154
crossref_primary_10_1053_j_seminoncol_2021_06_003
crossref_primary_10_1136_jim_2021_002298
crossref_primary_10_1038_s41565_025_01867_7
crossref_primary_10_1093_neuonc_noab041
crossref_primary_10_1186_s10020_023_00736_0
crossref_primary_10_2217_pme_2022_0099
crossref_primary_10_1080_14737167_2025_2456065
crossref_primary_10_1186_s12885_023_10899_y
crossref_primary_10_1002_ccr3_3892
crossref_primary_10_1186_s40644_023_00608_0
Cites_doi 10.1002/sim.1201
10.1093/ije/dys041
10.1126/science.3798106
10.1002/cncr.22885
10.1016/S1470-2045(17)30312-1
10.1056/NEJMoa1209124
10.1056/NEJMoa1814017
10.1200/JCO.2008.19.6618
10.1007/s10549-007-9885-0
10.1200/JCO.2014.57.1794
10.1080/03610929108830654
10.1016/j.jclinepi.2010.03.016
10.1016/S1470-2045(14)70178-0
10.1002/14651858.CD006243.pub2
10.1016/j.ejca.2013.07.142
10.1002/sim.6381
10.1634/theoncologist.2009-0181
10.3390/ijms20051115
10.1038/sj.onc.1210477
10.1080/10618600.1998.10474787
10.1200/JCO.2016.70.6267
10.1158/0008-5472.CAN-08-1776
10.1158/1538-7445
10.1200/JCO.2013.50.9984
ContentType Journal Article
Copyright The Author(s) 2020
COPYRIGHT 2020 Springer
Breast Cancer Research and Treatment is a copyright of Springer, (2020). All Rights Reserved. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: COPYRIGHT 2020 Springer
– notice: Breast Cancer Research and Treatment is a copyright of Springer, (2020). All Rights Reserved. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
K9-
K9.
M0R
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1007/s10549-020-05577-7
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Public Health Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
ProQuest Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Central Basic
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Research Library Prep
MEDLINE



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: Proquest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1573-7217
EndPage 609
ExternalDocumentID PMC7103014
A618892081
32100144
10_1007_s10549_020_05577_7
Genre Systematic Review
Journal Article
Network Meta-Analysis
GrantInformation_xml – fundername: F. Hoffmann-La Roche
  funderid: http://dx.doi.org/10.13039/100007013
– fundername: ;
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-XW
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
23N
28-
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8G5
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKNYI
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GRRUI
GUQSH
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
ICW
IHE
IHR
IHW
IJ-
IKXTQ
IMOTQ
INH
INR
ITC
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K9-
KDC
KOV
KOW
KPH
LAK
LLZTM
M0R
M1P
M2O
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z7W
Z81
Z82
Z83
Z87
Z8O
Z8Q
Z8U
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
H94
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c572t-c3e282bab09e203f91bbbf2215c9283d1218c9594948bdf0e7e814d5f721751f3
IEDL.DBID BENPR
ISICitedReferencesCount 29
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000516148700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0167-6806
1573-7217
IngestDate Tue Nov 04 02:00:47 EST 2025
Wed Oct 01 14:41:09 EDT 2025
Sat Nov 08 15:51:57 EST 2025
Sat Nov 29 13:06:13 EST 2025
Sat Nov 29 10:05:39 EST 2025
Thu May 22 21:21:11 EDT 2025
Wed Jul 02 01:57:02 EDT 2025
Tue Nov 18 21:54:30 EST 2025
Sat Nov 29 05:41:33 EST 2025
Fri Feb 21 02:31:53 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Trastuzumab emtansine
Lapatinib
Pertuzumab
Capecitabine
Neratinib
Locally advanced
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c572t-c3e282bab09e203f91bbbf2215c9283d1218c9594948bdf0e7e814d5f721751f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-3438-4853
OpenAccessLink https://link.springer.com/10.1007/s10549-020-05577-7
PMID 32100144
PQID 2383878029
PQPubID 36266
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7103014
proquest_miscellaneous_2365210844
proquest_journals_2383878029
gale_infotracmisc_A618892081
gale_infotracacademiconefile_A618892081
gale_healthsolutions_A618892081
pubmed_primary_32100144
crossref_primary_10_1007_s10549_020_05577_7
crossref_citationtrail_10_1007_s10549_020_05577_7
springer_journals_10_1007_s10549_020_05577_7
PublicationCentury 2000
PublicationDate 2020-04-01
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-04-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: Netherlands
– name: Dordrecht
PublicationTitle Breast cancer research and treatment
PublicationTitleAbbrev Breast Cancer Res Treat
PublicationTitleAlternate Breast Cancer Res Treat
PublicationYear 2020
Publisher Springer US
Springer
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer
– name: Springer Nature B.V
References Brooks, Gelman (CR30) 1998; 7
Cameron, Casey, Oliva, Newstat, Imwalle, Geyer (CR36) 2010; 15
Dieras, Miles, Verma, Pegram, Welslau, Baselga, Krop, Blackwell, Hoersch, Xu, Green, Gianni (CR13) 2017; 18
Cameron, Casey, Press, Lindquist, Pienkowski, Romieu, Chan, Jagiello-Gruszfeld, Kaufman, Crown, Chan, Campone, Viens, Davidson, Gorbounova, Raats, Skarlos, Newstat, Roychowdhury, Paoletti, Oliva, Rubin, Stein, Geyer (CR38) 2008; 112
CR19
Turner, Jackson, Wei, Thompson, Higgins (CR31) 2015; 34
von Minckwitz, du Bois, Schmidt, Maass, Cufer, de Jongh, Maartense, Zielinski, Kaufmann, Bauer, Baumann, Clemens, Duerr, Uleer, Andersson, Stein, Nekljudova, Loibl (CR32) 2009; 27
CR16
CR15
Lumley (CR23) 2002; 21
Turner, Davey, Clarke, Thompson, Higgins (CR42) 2012; 41
CR35
CR12
Lewis, Sreekumaran (CR27) 2015; 4
Verma, Miles, Gianni, Krop, Welslau, Baselga, Pegram, Oh, Dieras, Guardino, Fang, Lu, Olsen, Blackwell (CR10) 2012; 367
CR11
CR33
Lewis Phillips, Li, Dugger, Crocker, Parsons, Mai, Blattler, Lambert, Chari, Lutz, Wong, Jacobson, Koeppen, Schwall, Kenkare-Mitra, Spencer, Sliwkowski (CR8) 2008; 68
Salanti, Ades, Ioannidis (CR37) 2011; 64
Martin, Bonneterre, Geyer, Ito, Ro, Lang, Kim, Germa, Vermette, Wang, Wang, Awada (CR39) 2013; 49
CR2
Burstein, Keshaviah, Baron, Hart, Lambert-Falls, Marcom, Gelman, Winer (CR18) 2007; 110
Urruticoechea, Rizwanullah, Im, Ruiz, Lang, Tomasello, Douthwaite, Badovinac Crnjevic, Heeson, Eng-Wong, Munoz (CR26) 2017; 35
CR4
Rinnerthaler, Gampenrieder, Greil (CR9) 2019; 20
CR5
Krop, Kim, Gonzalez-Martin, LoRusso, Ferrero, Smitt, Yu, Leung, Wildiers (CR41) 2014; 15
CR7
Pivot, Manikhas, Zurawski, Chmielowska, Karaszewska, Allerton, Chan, Fabi, Bidoli, Gori, Ciruelos, Dank, Hornyak, Margolin, Nusch, Parikh, Nagi, DeSilvio, Santillana, Swaby, Semiglazov (CR17) 2015; 33
CR29
Robins, Tsiatis (CR34) 1991; 20
CR28
Moasser (CR1) 2007; 26
CR25
CR24
Moja, Tagliabue, Balduzzi, Parmelli, Pistotti, Guarneri, D′Amico (CR6) 2012
CR22
CR21
CR20
CR40
von Minckwitz, Huang, Mano, Loibl, Mamounas, Untch, Wolmark, Rastogi, Schneeweiss, Redondo, Fischer, Jacot, Conlin, Arce-Salinas, Wapnir, Jackisch, DiGiovanna, Fasching, Crown, Wulfing, Shao, Rota Caremoli, Wu, Lam, Tesarowski, Smitt, Douthwaite, Singel, Geyer (CR14) 2019; 380
Slamon, Clark, Wong, Levin, Ullrich, McGuire (CR3) 1987; 235
M Martin (5577_CR39) 2013; 49
5577_CR19
5577_CR35
D Cameron (5577_CR38) 2008; 112
RM Turner (5577_CR42) 2012; 41
G Rinnerthaler (5577_CR9) 2019; 20
5577_CR15
G von Minckwitz (5577_CR32) 2009; 27
5577_CR16
RM Turner (5577_CR31) 2015; 34
HJ Burstein (5577_CR18) 2007; 110
JM Robins (5577_CR34) 1991; 20
S Verma (5577_CR10) 2012; 367
GD Lewis Phillips (5577_CR8) 2008; 68
5577_CR11
5577_CR33
5577_CR12
G von Minckwitz (5577_CR14) 2019; 380
G Salanti (5577_CR37) 2011; 64
X Pivot (5577_CR17) 2015; 33
A Urruticoechea (5577_CR26) 2017; 35
L Moja (5577_CR6) 2012
DJ Slamon (5577_CR3) 1987; 235
5577_CR28
5577_CR29
D Cameron (5577_CR36) 2010; 15
MM Moasser (5577_CR1) 2007; 26
5577_CR24
5577_CR25
SP Brooks (5577_CR30) 1998; 7
V Dieras (5577_CR13) 2017; 18
MG Lewis (5577_CR27) 2015; 4
5577_CR4
5577_CR5
5577_CR2
IE Krop (5577_CR41) 2014; 15
5577_CR20
5577_CR21
5577_CR22
T Lumley (5577_CR23) 2002; 21
5577_CR40
5577_CR7
References_xml – ident: CR22
– volume: 21
  start-page: 2313
  issue: 16
  year: 2002
  end-page: 2324
  ident: CR23
  article-title: Network meta-analysis for indirect treatment comparisons
  publication-title: Stat Med
  doi: 10.1002/sim.1201
– volume: 41
  start-page: 818
  issue: 3
  year: 2012
  end-page: 827
  ident: CR42
  article-title: Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dys041
– volume: 235
  start-page: 177
  issue: 4785
  year: 1987
  end-page: 182
  ident: CR3
  article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
  publication-title: Science
  doi: 10.1126/science.3798106
– volume: 110
  start-page: 965
  issue: 5
  year: 2007
  end-page: 972
  ident: CR18
  article-title: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study
  publication-title: Cancer
  doi: 10.1002/cncr.22885
– ident: CR4
– volume: 18
  start-page: 732
  issue: 6
  year: 2017
  end-page: 742
  ident: CR13
  article-title: Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30312-1
– ident: CR2
– ident: CR16
– ident: CR12
– volume: 367
  start-page: 1783
  issue: 19
  year: 2012
  end-page: 1791
  ident: CR10
  article-title: Trastuzumab emtansine for HER2-positive advanced breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209124
– ident: CR33
– ident: CR35
– volume: 380
  start-page: 617
  issue: 7
  year: 2019
  end-page: 628
  ident: CR14
  article-title: Trastuzumab emtansine for residual invasive HER2-positive breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1814017
– ident: CR29
– volume: 27
  start-page: 1999
  issue: 12
  year: 2009
  end-page: 2006
  ident: CR32
  article-title: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.6618
– volume: 112
  start-page: 533
  issue: 3
  year: 2008
  end-page: 543
  ident: CR38
  article-title: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-007-9885-0
– volume: 33
  start-page: 1564
  issue: 14
  year: 2015
  end-page: 1573
  ident: CR17
  article-title: CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.1794
– volume: 20
  start-page: 2609
  year: 1991
  end-page: 2631
  ident: CR34
  article-title: Correcting for non-compliance in randomized trials using rank preserving structural failure time models
  publication-title: Comm Stat Theor Meth
  doi: 10.1080/03610929108830654
– ident: CR40
– ident: CR25
– volume: 4
  start-page: 1
  issue: 1
  year: 2015
  end-page: 9
  ident: CR27
  article-title: Review of applications of Bayesian meta-analysis in systematic reviews
  publication-title: Global Journal of Medicine and Public Health
– volume: 64
  start-page: 163
  issue: 2
  year: 2011
  end-page: 171
  ident: CR37
  article-title: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.03.016
– volume: 15
  start-page: 689
  issue: 7
  year: 2014
  end-page: 699
  ident: CR41
  article-title: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70178-0
– year: 2012
  ident: CR6
  article-title: Trastuzumab containing regimens for early breast cancer
  publication-title: Cochrane Database Syst Rev
  doi: 10.1002/14651858.CD006243.pub2
– volume: 49
  start-page: 3763
  issue: 18
  year: 2013
  end-page: 3772
  ident: CR39
  article-title: A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.07.142
– volume: 34
  start-page: 984
  issue: 6
  year: 2015
  end-page: 998
  ident: CR31
  article-title: Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis
  publication-title: Stat Med
  doi: 10.1002/sim.6381
– ident: CR21
– ident: CR19
– volume: 15
  start-page: 924
  issue: 9
  year: 2010
  end-page: 934
  ident: CR36
  article-title: Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0181
– ident: CR15
– volume: 20
  start-page: E1115
  issue: 5
  year: 2019
  ident: CR9
  article-title: HER2 Directed antibody-drug-conjugates beyond T-DM1 in breast cancer
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20051115
– volume: 26
  start-page: 6469
  issue: 45
  year: 2007
  end-page: 6487
  ident: CR1
  article-title: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210477
– ident: CR11
– volume: 7
  start-page: 434
  issue: 4
  year: 1998
  end-page: 455
  ident: CR30
  article-title: General methods for monitoring convergence of iterative simulations
  publication-title: J Comput Graph Stat
  doi: 10.1080/10618600.1998.10474787
– volume: 35
  start-page: 3030
  issue: 26
  year: 2017
  end-page: 3038
  ident: CR26
  article-title: Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.70.6267
– volume: 68
  start-page: 9280
  issue: 22
  year: 2008
  end-page: 9290
  ident: CR8
  article-title: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-1776
– ident: CR5
– ident: CR7
– ident: CR28
– ident: CR24
– ident: CR20
– volume: 110
  start-page: 965
  issue: 5
  year: 2007
  ident: 5577_CR18
  publication-title: Cancer
  doi: 10.1002/cncr.22885
– ident: 5577_CR33
– ident: 5577_CR35
– ident: 5577_CR16
– ident: 5577_CR4
– ident: 5577_CR12
– volume: 35
  start-page: 3030
  issue: 26
  year: 2017
  ident: 5577_CR26
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.70.6267
– volume: 18
  start-page: 732
  issue: 6
  year: 2017
  ident: 5577_CR13
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30312-1
– volume: 367
  start-page: 1783
  issue: 19
  year: 2012
  ident: 5577_CR10
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209124
– ident: 5577_CR22
– ident: 5577_CR40
  doi: 10.1158/1538-7445
– ident: 5577_CR24
– ident: 5577_CR19
– volume: 33
  start-page: 1564
  issue: 14
  year: 2015
  ident: 5577_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.1794
– volume: 26
  start-page: 6469
  issue: 45
  year: 2007
  ident: 5577_CR1
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210477
– volume: 7
  start-page: 434
  issue: 4
  year: 1998
  ident: 5577_CR30
  publication-title: J Comput Graph Stat
  doi: 10.1080/10618600.1998.10474787
– year: 2012
  ident: 5577_CR6
  publication-title: Cochrane Database Syst Rev
  doi: 10.1002/14651858.CD006243.pub2
– ident: 5577_CR28
– volume: 112
  start-page: 533
  issue: 3
  year: 2008
  ident: 5577_CR38
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-007-9885-0
– ident: 5577_CR20
– volume: 49
  start-page: 3763
  issue: 18
  year: 2013
  ident: 5577_CR39
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.07.142
– volume: 4
  start-page: 1
  issue: 1
  year: 2015
  ident: 5577_CR27
  publication-title: Global Journal of Medicine and Public Health
– volume: 64
  start-page: 163
  issue: 2
  year: 2011
  ident: 5577_CR37
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.03.016
– volume: 380
  start-page: 617
  issue: 7
  year: 2019
  ident: 5577_CR14
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1814017
– volume: 68
  start-page: 9280
  issue: 22
  year: 2008
  ident: 5577_CR8
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-1776
– volume: 20
  start-page: E1115
  issue: 5
  year: 2019
  ident: 5577_CR9
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20051115
– volume: 34
  start-page: 984
  issue: 6
  year: 2015
  ident: 5577_CR31
  publication-title: Stat Med
  doi: 10.1002/sim.6381
– volume: 235
  start-page: 177
  issue: 4785
  year: 1987
  ident: 5577_CR3
  publication-title: Science
  doi: 10.1126/science.3798106
– volume: 21
  start-page: 2313
  issue: 16
  year: 2002
  ident: 5577_CR23
  publication-title: Stat Med
  doi: 10.1002/sim.1201
– volume: 20
  start-page: 2609
  year: 1991
  ident: 5577_CR34
  publication-title: Comm Stat Theor Meth
  doi: 10.1080/03610929108830654
– ident: 5577_CR15
– ident: 5577_CR7
– volume: 15
  start-page: 689
  issue: 7
  year: 2014
  ident: 5577_CR41
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70178-0
– ident: 5577_CR2
  doi: 10.1200/JCO.2013.50.9984
– ident: 5577_CR5
– volume: 27
  start-page: 1999
  issue: 12
  year: 2009
  ident: 5577_CR32
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.6618
– ident: 5577_CR11
– volume: 41
  start-page: 818
  issue: 3
  year: 2012
  ident: 5577_CR42
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dys041
– volume: 15
  start-page: 924
  issue: 9
  year: 2010
  ident: 5577_CR36
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0181
– ident: 5577_CR29
– ident: 5577_CR25
– ident: 5577_CR21
SSID ssj0009709
Score 2.4427207
SecondaryResourceType review_article
Snippet Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments...
In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for...
Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments...
PurposeIn the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 597
SubjectTerms Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Bridged-Ring Compounds - administration & dosage
Cancer research
Care and treatment
Clinical trials
ErbB-2 protein
Female
Humans
Immunotherapy
Inhibitor drugs
Medicine
Medicine & Public Health
Meta-analysis
Metastases
Metastasis
Molecular Targeted Therapy
Monoclonal antibodies
Oncology
Pertuzumab
Receptor, ErbB-2 - antagonists & inhibitors
Review
Survival
Targeted cancer therapy
Taxoids - administration & dosage
Thrombocytopenia
Trastuzumab
Trastuzumab - administration & dosage
Treatment Outcome
SummonAdditionalLinks – databaseName: SpringerLINK Contemporary 1997-Present
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIMSF9yNQYJCQONCIvB1zq9BWPUCFClS9RbbjwErdLNpkV5T_jsSM7ew2K0CCy148cez1eDwTf_MNYy-EzOOGN3lYJIqHmVEqFKbEHyWjXEdKGlvr8OQdPzoqT0_FB58U1g1o9-FK0lrqC8luGMuEFO4QbxQP-WV2BY-7krbj8ceTDdUud8AOYvQuyqjwqTK_72N0HG0b5Qun0jZicuva1J5GBzf_bx632A3vfcK-U5fb7JJp77Br7_39-l32c-LJv9svgJ4hDHmT4GAf3jKCbGvoZGP6c5g3sMJwe77s4HBynIQOWW5qoIoPM4yRwVYhBxzjfAG9_C5b8xon1_XLH8uZVDBtwXO7dkAfhVESz2rs7-wcLAre1HuwtKREuqc8rz3Ajmaml5QLNdXutQ57tjKgCGTfgyZlXrwBCRuqanBpOnb0rUO_235C6YlZ7rHPB5NPbw9DXyAi1DlP-lCnBiNGJVUkTBKljYiVUk2CXowW6DbVMfovWuSCKHBU3USGmzLO6rzBsJejjqb32U47b81DBnWTaq5SlRljsshodNt0pGMtssJI3hQBiwc9qbRnT6ciHmfVhveZ1rXCda3sulY8YK_Wz3xz3CF_lX5G6le5_Ne14an2i7gsRYKuW8BeWgkyPfhuLX0GBc6ASLxGkrsjSTQZetw8qHjlTVZXoe-WlryMEhGw5-tmepJgeK3BhUeZAt29qMyygD1wO2I9M0oGo_A8YHy0V9YCRGQ-bmmnXy2hOY9tZB-wvWHHbIb15z_s0b-JP2bXE7vpCHW1y3b6xdI8YVf1qp92i6fWhPwCFbVxzg
  priority: 102
  providerName: Springer Nature
Title Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
URI https://link.springer.com/article/10.1007/s10549-020-05577-7
https://www.ncbi.nlm.nih.gov/pubmed/32100144
https://www.proquest.com/docview/2383878029
https://www.proquest.com/docview/2365210844
https://pubmed.ncbi.nlm.nih.gov/PMC7103014
Volume 180
WOSCitedRecordID wos000516148700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Consumer Health Database
  customDbUrl:
  eissn: 1573-7217
  dateEnd: 20201231
  omitProxy: false
  ssIdentifier: ssj0009709
  issn: 0167-6806
  databaseCode: M0R
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/familyhealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Proquest Central
  customDbUrl:
  eissn: 1573-7217
  dateEnd: 20201231
  omitProxy: false
  ssIdentifier: ssj0009709
  issn: 0167-6806
  databaseCode: BENPR
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1573-7217
  dateEnd: 20201231
  omitProxy: false
  ssIdentifier: ssj0009709
  issn: 0167-6806
  databaseCode: 7X7
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Public Health Database
  customDbUrl:
  eissn: 1573-7217
  dateEnd: 20201231
  omitProxy: false
  ssIdentifier: ssj0009709
  issn: 0167-6806
  databaseCode: 8C1
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 1573-7217
  dateEnd: 20201231
  omitProxy: false
  ssIdentifier: ssj0009709
  issn: 0167-6806
  databaseCode: M2O
  dateStart: 20200101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1573-7217
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009709
  issn: 0167-6806
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYhxAvfH8ExjgkJB5otHw74QWNqdMeWJkKTH2LbMeBSms6mrRi_O9I3DluSyqxF14sRb44ueR8vrPvfsfY60zEfsnL2E0Cyd1IS-lmOsVGCi9WnhTa1Do8_8iHw3Q8zs7shlttwypXOtEo6mKmaI_8AJeWMOWpF2TvL3-4VDWKTldtCY0dtktIZVGP7X4YDM9GG9hd3gZ5ELp3knqJTZuxyXPoG7nkPhEOFXd5Z2naVtB_rVDb0ZNbR6hmZTq--7883WN3rE0Kh60Q3Wc3dPWA3Tq1p-4P2e-BhQSvvgHai7DKpoQ2GMTqSxBVAbUodXMFsxKW6ITPFjWcDEaB28ab6wKoDsQUPWcwtckBOZrNoRE_RaUPkM26WfxaTIWESQUW8bUG2ipGSlzBcbyLKzCx8brow8JAFamGsr_6gANNdSMoQ2qi2se2EWlLDZJC7xtQJOLzdyBgA2ANbfKOefuqjYk347jCwrU8Yl-PB1-OTlxbNsJVMQ8aV4Ua_UgppJfpwAvLzJdSlgHaNipDY6rw0apRWZwRMI4sSk9znfpREZfoDHOU3PAx61WzSj9lUJSh4jKUkdY68rRCY055yldZlGjBy8Rh_kpicmUx1am0x0W-QYMmKctRynIjZTl32Nv1PZctosi11C9JEPM2K3atjvLDxE_TLECDzmFvDAUpJHy2EjavAjkgaK8O5V6HEhWJ6navpDS3iqzONyLqsFfrbrqTgvMqjT8eaRI0Ar00ihz2pJ0ba84oRYycdofxzqxZExC8ebenmnw3MOfcN_6-w_qr-bV5rX9_sGfXc_Gc3Q7MlKfYqz3Wa-YL_YLdVMtmUs_32Q4fc9Om2KZH_r5VKHh16pk2-ITt6PP5H5xXgrk
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELfGQMAL3x-BwQ4JxAONlqRJnCAhNI1OndZVCA20t2A7DlRa09GkhfJH8R8iceckLanE3vbAS158cWLHd-dzfvc7xp7HInAzngV26Elu-1pKO9YRXqRwAuVIoU2tw08DPhxGJyfx-w32q8mFIVhlYxONoU4nis7Id9C1dCMeOV789uybTVWj6O9qU0KjWhaHevEdQ7bizcE7_L4vPG-_d7zXt-uqArYKuFfaqqsxzJBCOrH2nG4Wu1LKzEPXp2L0tamLTk_FQUy8KTLNHM115PppkGGsxHFgXez3ErtMTHYU7EV7K0hJzCtICXGJh5ET1kk6daoeRmI2BWvEesVt3nKE6-7gL3-4jtVc-2Fr_OD-zf9tBm-xG_WOG3YrFbnNNnR-h109qjEFd9nvXk14nn8B3A1DkysKFdSl9gYg8hQKkelyAZMM5mJK4GHo9z54doWm1ylQlYuxzlGYKq8DzuBkCqX4IXK9g9NalLOfs7GQMMqh5rMtgA7CURL3J9jf6QIM8l-nHZgZIiZVUm5bB7CjsS4F5X-NVPXYCm831yApsaAERQo8fQ0CVvTcUKUmmbfPK8S_6ccWNRnNPfbxQib_PtvMJ7l-yCDNuorLrvS11r6jFW5VlaNcFfuhFjwLLeY2KzRRNWM8FS45TVZc17SqE1zViVnVCbfYq-U9ZxVfyrnS27Twkyrnd2lsk93QjaLYw-2qxV4aCTK3-Gwl6qwRHAERl7Ukt1qSaCZVu7nRiqQ200WyUgmLPVs2050EPcw1fniUCXGL60S-b7EHlS4uR0YJcHQkYTHe0tKlAJG3t1vy0VdD4s5dc5phsU6jz6vX-veEPTp_FNvsWv_4aJAMDoaHj9l1z5gbQpltsc1yOtNP2BU1L0fF9KkxXMA-X7Se_wHjvdcQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMv3C-BwQ4SiAcaNbfGCRJC09Zq00Y1IUB7C7bjQKU1HW1aKD-N_4bEOY7T0krsbQ-85MUnTuyci-2c7zuMPU9Fxy940XHjQHI30lK6qU7wIoXXUZ4U2tQ6_HTM-_3k9DQ92WC_GiwMpVU2PtE46nyk6Iy8jaElTHjiBWm7sGkRJ_u9t-ffXKogRX9am3IatYoc6fl33L5N3hzu47d-EQS97oe9A9dWGHBVhweVq0KNWw4ppJfqwAuL1JdSFgGGQZVi3M19DIAq7aTEoSLzwtNcJ36UdwrcN3EcZIj9XmFXeYhaTCj1vWV6Scrr9BLiFY8TL7aAHQvbw12ZSxs3YsDiLl8Jiuuh4a_YuJ63ufbz1sTE3s3_eTZvsRt2JQ67tencZhu6vMO23tlcg7vsd9cSoZdfAFfJ0GBIoU6BsVECRJnDRBS6msOogJkYU1IxHHTfB26dZa9zoOoXQ12iMFVkB5zN0Rgq8UOUuo1TPKmmP6dDIWFQguW5nQAdkKMkrluwv7M5GESAzlswNQRNqiLMWwuwo6GuBOHCBqp-bJ2HN9MgCXBQgSLDHr8GAUvabqghS-btyxoJYPpxhSWpucc-Xsrk32eb5ajUDxnkRai4DGWktY48rXAJqzzlqzSKteBF7DC_0dZMWSZ5Kmhyli05sEnDM9TwzGh4xh32anHPec2jcqH0DhlBVmOBF0442439JEkDXMY67KWRIDeMz1bCoklwBERotiK5vSKJ7lOtNjcWkln3PcmW5uGwZ4tmupNSEkuNHx5lYlz6ekkUOexBbZeLkREwjo4qHMZXLHYhQKTuqy3l4Kshd-e-OeVwWKux7eVr_XvCHl08ih22headHR_2jx6z64HxPJR8ts02q_FUP2HX1KwaTMZPjQ8D9vmyzfwPQhff1Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+the+clinical+effectiveness+and+safety+of+various+HER2-targeted+regimens+after+prior+taxane%2Ftrastuzumab+in+patients+with+previously+treated%2C+unresectable%2C+or+metastatic+HER2-positive+breast+cancer%3A+a+systematic+review+and+network+meta-analysis&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=Paracha%2C+Noman&rft.au=Reyes%2C+Adriana&rft.au=Di%C3%A9ras%2C+V%C3%A9ronique&rft.au=Krop%2C+Ian&rft.date=2020-04-01&rft.pub=Springer&rft.issn=0167-6806&rft.volume=180&rft.issue=3&rft.spage=597&rft_id=info:doi/10.1007%2Fs10549-020-05577-7&rft.externalDocID=A618892081
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon